Label Changes for:
Xgeva (denosumab)
September 2012
Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
September 2012
5 WARNINGS AND PRECAUTIONS
5.2 Osteonecrosis of the Jaw (ONJ)
- In clinical trials in patients with osseous metastasis, 2.2% of patients receiving Xgeva developed ONJ after a median exposure of 13 doses; of these patients, ......
April 2012
